Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Insulin Lispro Protamine Suspension, Insulin Lispro Protamine Suspension (ILPS)
Insulin Lispro Protamine · 4 trials · 3 indications
Least squares mean values were controlled for Baseline + Baseline HbA1c Group + Baseline sulfonylurea (SU) Group.
| Arm | Type | Description |
|---|---|---|
| ILPS | ACTIVE_COMPARATOR | Insulin Lispro Protamine Suspension (ILPS) |
| Glargine | ACTIVE_COMPARATOR | Insulin Glargine |
| Insulin Lispro Protamine Suspension | EXPERIMENTAL | Insulin Lispro Protamine Suspension: Patient specific dose administered subcutaneously once daily or twice daily x 24 weeks. |
| Detemir | ACTIVE_COMPARATOR | Detemir: Patient specific dose administered subcutaneously once or twice daily x 24 weeks. |
| Lispro | EXPERIMENTAL | Insulin Lispro protamine suspension: Patient adjusted dose, once daily (QD) or twice daily (BID), injected subcutaneous (SC) x 24 weeks |
| Name | Type | Description |
|---|---|---|
| Insulin Lispro Protamine Suspension | DRUG | Administered subcutaneously once a day at bedtime |
| Insulin Glargine | DRUG | Administered subcutaneously once a day at bedtime |
| Detemir | DRUG | Patient specific dose administered subcutaneously once or twice daily x 24 weeks. |
| Insulin Levemir | DRUG | Patient specific dose insulin Levemir (detemir) twice daily (BID) subcutaneous (SC) injection x 32 weeks |
Inclusion Criteria: * Must have type 2 diabetes * Must be at least 18 years of age and less than 75 years of age * Must be taking exenatide 10 micrograms twice a day (BID) for at least 3 months * Must be taking one of the following oral diabetes medication regimens for at least 3 months: (1) metfor...
Insulin Lispro Protamine is an investigational basal insulin developed by Eli Lilly and Company for the treatment of type 1 and type 2 diabetes mellitus. It is a protamine suspension form of insulin lispro designed to provide longer-acting insulin coverage. It is also known as Insulin Lispro Protamine Suspension, or ILPS.
Insulin Lispro Protamine is being studied for glycemic control in adults with type 2 diabetes mellitus and type 1 diabetes mellitus. The clinical program has evaluated it as a basal insulin in patients already taking anti-hyperglycemic medications, including oral diabetes medicines and exenatide.
Insulin Lispro Protamine targets INSR, the insulin receptor, and acts as an agonist. By activating the insulin receptor, it supports glucose uptake and lowers blood glucose, which is the basis for its use as a basal insulin in diabetes management.
Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY, is the developer of Insulin Lispro Protamine. The company has sponsored the clinical trial program evaluating this basal insulin in patients with type 1 and type 2 diabetes.
Insulin Lispro Protamine is in Phase 3 development. It is investigational and has not been approved by the FDA. Three completed Phase 3 trials have enrolled a total of 1,252 participants, and no active trials are currently listed for this asset.
The Phase 3 program includes NCT00560417, NCT00510952, and NCT00494013 in type 2 diabetes, plus NCT00487240 in type 1 diabetes. All four trials are completed, were randomized and active-controlled, and enrolled adults aged 18 years and older across multiple countries.
Yes. Insulin Lispro Protamine is also known as Insulin Lispro Protamine Suspension, abbreviated ILPS. These names refer to the same Eli Lilly basal insulin product candidate, so searches using either name point to the same investigational asset.